Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | RPA1 | P27694 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15546231 | 0.91 | MEN1 (0.53) | MEN1KMT2ARXFP1UTS2RHPGD | |
| SCHEMBL15546529 | 0.90 | MEN1 (0.49) | MEN1KMT2ARXFP1HPGDSMN1; SMN2 | |
| SCHEMBL28819583 | 0.85 | KMT2A (0.50) | MEN1KMT2ARXFP1HPGDSMN1; SMN2 | |
| SCHEMBL15546009 | 0.83 | KMT2A (0.66) | MEN1KMT2ARXFP1HPGDSMN1; SMN2 | |
| SCHEMBL16907796 | 0.82 | MEN1 (0.47) | MEN1KMT2ARXFP1UTS2RMAPT | |
| SCHEMBL16893373 | 0.82 | MEN1 (0.52) | MEN1KMT2ARXFP1HPGDMAPT | |
| SCHEMBL15547477 | 0.82 | KMT2A (0.48) | MEN1KMT2ARXFP1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16893531 | 0.81 | KMT2A (0.48) | MEN1KMT2ARXFP1HPGDSMN1; SMN2 | |
| SCHEMBL16893415 | 0.81 | MEN1 (0.46) | MEN1KMT2ARXFP1UTS2RSMN1; SMN2 | |
| SCHEMBL16893414 | 0.81 | MEN1 (0.46) | MEN1KMT2ARXFP1UTS2RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | claimed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | claimed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | claimed |
| EP-2875010-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | Metabrain Research (FR) | 2015-05-27 | — | — | EP | claimed |
| WO-2014013181-A1 | THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2014-01-23 | — | — | WO | claimed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| EP-2875010-B1 | THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | METABRAIN RES (FR) | 2016-08-31 | — | — | EP | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, TPMT | MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.